https://www.selleckchem.com/pr....oducts/GSK872-GSK239
.001). Adjusted long-term survival following cancer treatment at affiliate hospitals was only 77% that of top-ranked hospitals (time ratio, 0.77 [95% CI, 0.72-0.83]; P less then .001). The survival advantage was not fully explained by differences in annual surgical volume, with both long- and short-term survival remaining superior at top-ranked hospitals even after models were adjusted for volume. Conclusions and relevance These findings suggest that short- and long-term survival after complex cancer treatment were superior a